Talk:Lapatinib

The
"The exact site of binding has currently not been confirmed (EGFR and ErbB2 have a number of intracellular phosphorylation sites)." -- this should probably be removed, at least for EGFR, since there's a crystal structure of Lapatinib bound to the ATP binding site from 2004: pdb code 1XKK.

Lapatinib is well known as an ATP-competitive kinase inhibitor (that was determined well before the crystal structure being solved). The comment has been removed. 05:52, 18 December 2007 (UTC)btavshan


 * Its identity as a kinase inhibitor is explicated in the third paragraph, if that wasn't obvious enough from the name. Could you point to when/where/what was actually removed? Otherwise, I can't tell if any information is missing that could go in there. Someguy1221 (talk) 05:57, 18 December 2007 (UTC)

Lapatinib
Lapatinib is a yellow solid having a solubility of 0.007 mg/ml in water at 25 degrees centigrade. The drug (Lapatinib Ditosylate) marketed by GSK, has been found to be effective in the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have recieved prior therapy including an anthracycline, a taxane and trastuzumab. It is prescribed in combination with capacetabine as a ditosylate salt.

News re combo trial for HER2 breast cancer
Anti-HER2 Combo Shrunk Breast Tumors in Under 2 Weeks "A quarter of women with HER2-positive breast cancer treated with a combination of lapatinib plus trastuzumab prior to surgery had significant tumor shrinkage within 11 days." - Rod57 (talk) 03:00, 12 March 2016 (UTC)

as ditosylate
Most of the article seems to be talking about lapatinib ditosylate but the molecular structure and molecular formula are of the bare lapatinib. Presumably, in principle, different forms of lapatinib could exist and be licenced so we should clarify which content applies to just the ditosylate form. We could note where on lapatinib the two? tosylates are attached, and say under what conditions (pH ?) they dissociate. eg during oral administration and absorption where/do the tosylates detatch ? - Rod57 (talk) 14:05, 13 July 2017 (UTC)

External links modified
Hello fellow Wikipedians,

I have just modified 3 external links on Lapatinib. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
 * Added archive https://web.archive.org/web/20080615022955/http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10063.htm to http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10063.htm
 * Added archive https://web.archive.org/web/20081126082044/http://www.ecco-org.eu/News/Press-room/Press-release/page.aspx/439?xf_itemId=265&xf_catId=27 to http://www.ecco-org.eu/News/Press-room/Press-release/page.aspx/439?xf_itemId=265&xf_catId=27
 * Added archive https://web.archive.org/web/20150110162423/http://www.bioportfolio.com/news/article/1492867/GSK-Tykerb-Tyverb-Phase-III-gastric-cancer-study-fails-to-meet-primary.html to http://www.bioportfolio.com/news/article/1492867/GSK-Tykerb-Tyverb-Phase-III-gastric-cancer-study-fails-to-meet-primary.html

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

Cheers.— InternetArchiveBot  (Report bug) 02:02, 17 December 2017 (UTC)